<DOC>
	<DOC>NCT00073489</DOC>
	<brief_summary>The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.</brief_summary>
	<brief_title>A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description>The primary objective of this study is to determine the activity of OSI-461 given twice daily orally in previously untreated CLL patients. The secondary objective is to evaluate the safety profile of OSI-461 in this patient population.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Diagnosis of CLL established by bone marrow aspiration and biopsy or flow cytometry of peripheral blood. No previous therapy for CLL. Expected remaining life span greater than or equal to six months. 18 years or older. Willingness and ability to sign an informed consent. Other active malignancy or history of treatment of any malignancy (excluding nonmelanoma skin cancer) within the previous three years. History of other malignancy which could affect the diagnosis or assessment of OSI461. Previous therapy for CLL. Use of an investigational medication or device within one month of initiating study therapy. Concurrent immunotherapy. Use of steroids at the time of enrollment (patients who require steroids after enrollment may remain on study). Any condition or any medication which may interfere with the conduct of the study. Serious uncontrolled intercurrent medical or psychiatric illness, including serious infection. Evidence of CNS involvement. Pregnant or nursing women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>chronic leukemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>